Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009:4:63-5.
Epub 2009 May 14.

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis

Dimitrios Karagiannis  1 , Ilias Georgalas, Ioannis Ladas, Parikakis Eustratios, Panagiotis Mitropoulos
Affiliations
Case Reports

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis

Dimitrios Karagiannis et al. Clin Interv Aging. 2009.

Abstract

A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.

Keywords: idiopathic juxtafoveal retinal telangiectasis; ranibizumab; subretinal neovascularization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A) Right eye: Color fundus picture showing slightly dilated right-angle veins with retinal pigment epithelium hyperplasia beneath them. B) Left eye: Color fundus picture showing subretinal hemorrhage inferior and temporal to the fovea. C) Venous phase of FA of the LE depicts early hyperfluorescence corresponding to the neovascular membrane and hypofluorescence inferior to the membrane corresponding to the subretinal hemorrhage. D) Late phase of FA showing leakage from the neovascular membrane. Abbreviations: FA, fluorescein angiography; LE, left eye; OCT, optical coherence tomography.
Figure 2
Figure 2
Oblique section of OCT of the LE. Abbreviations: LE, left eye; OCT, optical coherence tomography.
Figure 3
Figure 3
A) Oblique section of OCT of the LE revealing the characteristic appearance of outer and inner retina having similar reflectivity and an area temporal to the fovea with high reflectivity corresponding to the temporal area of choroidal neovascularization observed in the angiogram. B) OCT of the same section of LE revealing significant reduction in retinal thickness. The RPE remains thickened. Abbreviations: LE, left eye; OCT, optical coherence tomography; RPE, retinal pigment epithelium.
Figure 4
Figure 4
A) Left eye: Color fundus picture following ranibizumab treatment revealing significant improvement with no subretinal hemorrhage. B) late venous phase of FA of the LE showing minimal leakage due to telangiectasis but no signs of active neovascular membrane. Abbreviations: FA, fluorescein angiography; LE, left eye.
See this image and copyright information in PMC

References

    1. Gass JD, Blodi BA. Idiopathic juxtafoveal retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536–1546. - PubMed
    1. Engelbrecht NE, Aaberg TM, Jr, Sung J, Lewis ML. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol. 2002;120:320–324. - PubMed
    1. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124:450–460. - PubMed
    1. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2004;137:812–819. - PubMed
    1. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Eighteen-month follow-up of intravitreal bevacizumab in type 2idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92:941–945. - PubMed

Publication types

LinkOut - more resources